The submission includes data indicating a meaningful survival benefit for infantile-onset NPC patients treated with adrabetadex.
The NDA is based on results from the Phase III evERA Breast Cancer study. Credit: NMK-Studio / Shutterstock.com. (NMK-Studio / Shutterstock.com.) Roche has obtained acceptance from the US Food and ...
Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for giredestrant, an investigational oral ...
Using proprietary copolymer technology, TEV-’749 allows for a controlled steady release of olanzapine, a second generation antipsychotic.
The Barstool Sports personality appeared on Logan Paul’s “Impaulsive” podcast and dubbed Bryan’s relationship with his wife a ...